SCHEMBL34463164

SCHEMBL34463164

CCOC(=O)c1ccc(-c2ccnc(Nc3cccc(N4CCN(C)CC4)c3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 2/20 0.61
▸ LDLR P01130 1/20 0.61
▸ PCSK9 Q8NBP7 1/20 0.61
▸ JAK2 O60674 8/20 0.59
▸ JAK3 P52333 3/20 0.58
▸ FLT3 P36888 4/20 0.54
▸ CDK2 P24941 4/20 0.54
▸ SYK P43405 3/20 0.54
▸ SRC P12931 2/20 0.54
▸ GSK3B P49841 2/20 0.54
▸ PLK4 O00444 1/20 0.54
▸ CHEK1 O14757 1/20 0.54
▸ PRKD3 O94806 1/20 0.54
▸ LCK P06239 1/20 0.54
▸ CSF1R P07333 1/20 0.54
▸ ROS1 P08922 1/20 0.54
▸ FGFR1 P11362 1/20 0.54
▸ FLT1 P17948 1/20 0.54
▸ FGFR3 P22607 1/20 0.54
▸ MARK3 P27448 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34463169 0.87 JAK2 (0.65) KITLDLRPCSK9JAK2JAK3
SCHEMBL27387217 0.82 JAK2 (0.64) KITLDLRPCSK9JAK2JAK3
SCHEMBL30788196 0.82 JAK2 (0.64) KITLDLRPCSK9JAK2JAK3
SCHEMBL2856029 0.80 JAK2 (0.72) JAK2JAK3CDK2PLK4PRKD3
SCHEMBL4903303 0.77 ABL1 (0.66) JAK2SYKSRCGSK3BPRKD3
SCHEMBL30788197 0.77 KIT (0.55) KITLDLRPCSK9JAK2JAK3
SCHEMBL27387276 0.77 KIT (0.55) KITLDLRPCSK9JAK2JAK3
SCHEMBL27387222 0.77 KIT (0.55) KITLDLRPCSK9JAK2JAK3
SCHEMBL30788203 0.77 KIT (0.55) KITLDLRPCSK9JAK2JAK3
SCHEMBL2384044 0.77 JMJD6 (0.49) HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103455-A1 ULK3 INHIBITORS AND USES THEREOF H LEE MOFFITT CANCER CT & RES (US) 2026-04-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103455-A1 ULK3 INHIBITORS AND USES THEREOF ULK3, ULK1, ULK2 KIT 1917/4885LDLR 1853/4885PCSK9 4067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback